Skip to main content

Table 1 Studies Comparing Outcomes in Advanced Malignancy Patients on Treatment with Anti-Programmed Cell Death Protein 1 (PD-1) and Anti-Programmed Death-Ligand 1 (PD-L1) Antibodies

From: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

StudyDiseaseNumber of PatientsCheckpoint Inhibitor(s) UsedSurvival Endpoints Between Patients With and Without IRAESResponse Endpoints Between Patients With and Without IRAEs
Grangeon et al. [18]NSCLC270Anti-PD-1 and anti-PD-L1OS (HR 0.29; 95% CI 0.18–0.46; p = .001), PFS (HR 0.42; 95% CI 0.32–0.57; p < .001)ORR (22.9% vs 5.7%, p < .0001), DCR (76% vs 58%, p < .001)
Ricciuti et al. [34]NSCLC195NivolumabOS (HR 0.33; 95% CI 0.23–0.47; p < .001), PFS (HR 0.41; 95% CI 0.3–0.57; p < .001)ORR (43.5% vs 10%, p < .001), DCR (70.5% vs 18.1%, p < .0001)
Riudavets et al. [13]NSCLC, UCC and melanoma178Nivolumab, pembrolizumab and atezolizumabOS (37.3 vs 7.8 months, p < 0.0001), PFS (7.9 vs 2.6 months, p < 0.0001)Not provided
Sato et al.a [19]NSCLC38NivolumabPFS (HR 0.1; 95% CI .02–.37; p < .001)ORR (63.6% vs 7.4%, p < .01)
Weber et al. [38]Melanoma576NivolumabPFS (no significant differences between either group; HR or p value not provided)ORR (48.6% vs 17.8%, p < .001)
Indini et al. [37]Melanoma173Anti-PD-1OS (HR 0.39; 95% CI 0.18–0.81; p = .007), PFS (HR 0.47; 95% CI 0.26–0.86; p = .016)ORR (HR 1.95; 95% CI 0.91–4.15; p < 0.082), DCR (HR 1.98; 95% CI 1.07–3.67; p < 0.029)
Elias et al. [17]RCC90Anti-PD-1OS (HR 0.38; 95% CI 0.18–0.79; p = .01) and TTNT (HR 0.48; 95% CI 0.28–0.83; p = .008)Not provided
Verzoni et al. [39]RCC389NivolumabOS (HR .57; 95% CI .35–.93; p = .02)Not provided
Maher et al. [20]UCC1747Atezolizumab or pembrolizumabOS (HR 0.53; 95% CI 0.43–0.66)Not provided
Morales-Berera et al. [40]UCC52Anti-PD-1 or anti-PD-L1OS (21.91 vs 6.47 months, p = .004)DCR (79% vs 36.3%, p = .002)
Das et al. [41]GI61Anti-PD-1 monotherapy or in combinationOS (32.4 vs 8.5 months, p = .0036), PFS (32.4 vs 4.8 months, p = .0001)Not provided
Masuda et al. [42]Gastric65NivolumabOS (HR .17, p < .001), PFS (HR .11, p < .001)Not provided
Foster et al. [43]HNSCC114Anti PD-1OS (12.5 vs 6.8 months, p = .0007), PFS (6.9 vs 2.1 months, p = .0004)ORR (30.6% vs 12.3%, p = .02)
  1. Abbreviations: NSCLC non-small cell lung cancer, UCC urothelial cell carcinoma, RCC renal cell carcinoma, GI gastrointestinal, HNSCC head and neck squamous cell carcinoma, IRAEs immune related adverse events, OS overall survival, PFS progression-free survival, ORR overall response rate, DCR disease control rate, HR hazard ratio, CI confidence interval, TTNT time to next treatment, vs versus
  2. aProspective study